               SEQUENCE LISTING

<110> Bioorganic Research and Services SA

<120> FORMULATIONS FOR NON-INVASIVE DELIVERY OF ACTIVE PROTEINS TO AN ANIMAL OR HUMAN

<160> 5

<170> BiSSAP 1.0

<210> 1
<211> 109
<212> PRT
<213> Bombyx mori

<220> 
<221> SOURCE
<222> 1..109
<223> /mol_type="protein"
      /organism="Bombyx mori"

<400> 1
His Gly Ala Arg Phe Lys Arg Lys Leu Gln Arg Arg Leu Thr Arg Gln 
1               5                   10                   15    
Ala Leu Ala Glu Ala Lys Ala Ile Lys Glu Gln Ile His Val Leu Val 
            20                   25                  30        
Tyr Val Ala Glu Leu Val Ala Lys Asp Pro Val Leu Ala Trp Lys Lys 
        35                   40                  45            
Ala Lys Glu Leu Tyr Ala Ser Leu Ser Gln Pro Glu Pro Glu Asn Gln 
    50                   55                  60                
Ala Arg Pro Val Thr Leu Glu Glu Leu Met Val Leu Leu Thr Arg Glu 
65                   70                  75                  80
Thr Ala Arg Lys Val Val His Leu Val Asn Tyr Thr His Thr Asp Leu 
                85                   90                  95    
Pro Arg Asn Ile Arg Gln Gly Met Ser Ile Val Tyr Lys 
            100                  105                

<210> 2
<211> 72
<212> PRT
<213> artificial sequences

<220> 
<221> SOURCE
<222> 1..72
<223> /mol_type="protein"
      /note="Human caveolin-2 derived sequence"
      /organism="artificial sequences"

<400> 2
Trp Ile Cys Ser His Ala Leu Phe Glu Ile Ser Lys Tyr Val Met Tyr 
1               5                   10                   15    
Lys Leu Leu Val Leu Leu Val Leu Leu Val Leu Leu Val Leu Leu Val 
            20                   25                  30        
Leu Leu Val Leu Leu Val Leu Leu Val Lys Thr Cys Leu Met Val Leu 
        35                   40                  45            
Pro Ser Val Gln Thr Ile Trp Lys Ser Val Thr Asp Val Ile Ile Ala 
    50                   55                  60                
Pro Leu Cys Thr Ser Val Gly Arg 
65                   70        

<210> 3
<211> 45
<212> PRT
<213> artificial sequences

<220> 
<221> SOURCE
<222> 1..45
<223> /mol_type="protein"
      /note="Human caveolin-2 derived sequence"
      /organism="artificial sequences"

<400> 3
Trp Ile Cys Ser His Ala Leu Phe Glu Ile Ser Lys Tyr Val Met Tyr 
1               5                   10                   15    
Lys Leu Leu Val Leu Leu Val Leu Leu Val Leu Leu Val Leu Leu Val 
            20                   25                  30        
Leu Leu Val Leu Leu Val Leu Leu Val Lys Asp Glu Leu 
        35                   40                  45

<210> 4
<211> 87
<212> PRT
<213> Apis

<220> 
<221> SOURCE
<222> 1..87
<223> /mol_type="protein"
      /organism="Apis"

<400> 4
Ile Asp Ile Gln Asp Leu Phe Asp Lys Ser Arg Phe Pro Ser Gly Trp 
1               5                   10                   15    
Arg Leu Ile Phe Ile Phe Leu Tyr Thr Pro Val Gly Ile Leu Leu Val 
            20                   25                  30        
Leu Leu Arg Leu Leu Ile Ala Leu Gln Leu Trp Leu Val Ala Ile Leu 
        35                   40                  45            
Leu Pro Asp Cys Asn Ile Leu Arg Thr Phe Leu Ser His Gly Phe Ser 
    50                   55                  60                
Phe Ala Phe Gly Ile Leu Val Lys Ile Pro Glu Gly Glu Val Lys Asp 
65                   70                  75                  80
Lys Gln Ser Arg Ile Ile Ile 
                85        

<210> 5
<211> 28
<212> PRT
<213> artificial sequences

<220> 
<221> SOURCE
<222> 1..28
<223> /mol_type="protein"
      /note="Polyproline sequence"
      /organism="artificial sequences"

<400> 5
Pro Val His Pro Pro His His Pro Val His Pro Pro His His Pro Val 
1               5                   10                   15    
His Pro Pro His His Pro Val His Pro Pro His His 
            20                   25            

